SCHEMBL143175

SCHEMBL143175

O=c1ccccn1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
KDM4E B2RXH2 1/20 0.54
CYP1A2 P05177 1/20 0.54
HPGD P15428 1/20 0.54
BLM P54132 1/20 0.54
HSD17B10 Q99714 1/20 0.54
ATM Q13315 1/20 0.50
DDB1 Q16531 1/20 0.50
CRBN Q96SW2 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 1/20 0.48
MCL1 Q07820 1/20 0.48
COMT P21964 1/20 0.44
MGLL Q99685 1/20 0.42
EP300 Q09472 1/20 0.41
KAT2B Q92831 1/20 0.41
GAA P10253 2/20 0.41
GSK3A P49840 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2645575 0.83 DDB1 (0.41) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD
SCHEMBL2539751 0.81 F10 (0.39) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD
SCHEMBL29348735 0.81 F10 (0.52) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD
SCHEMBL142916 0.81 MEN1 (0.54) ALDH1A1MEN1KMT2AMAPTMCL1
SCHEMBL2531715 0.81 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD
SCHEMBL1277801 0.81 FAAH (0.43) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD
SCHEMBL92819 0.81 KDM4E (0.57) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD
SCHEMBL142777 0.81 F10 (0.44) ALDH1A1KDM4EMGLLF10
SCHEMBL3561936 0.81 CA12 (0.50) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD
SCHEMBL4212713 0.81 F10 (0.56) ALDH1A1ATMMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514348-A2 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) Noetix Pharma LLC (US) 2025-03-05 EP claimed
US-20240299698-A1 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) NOETIX PHARMA LLC 2024-09-12 US claimed
CN-114716365-B Application of N-substituted phenyl-2-pyridone compound or pharmaceutically acceptable salt thereof in treatment of pulmonary fibrosis 大连理工大学 2024-03-01 CN claimed
WO-2023211684-A2 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) NOETIX PHARMA LLC (US) 2023-11-02 WO claimed
CN-116655654-A N-substituted phenyl-2-pyridone endoperoxide and application thereof 大连理工大学 2023-08-29 CN claimed
WO-2022200523-A9 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2023-02-16 WO claimed
CN-114716365-A Application of N-substituted phenyl-2-pyridone compounds or pharmaceutically acceptable salts thereof in treating pulmonary fibrosis 大连理工大学 2022-07-08 CN claimed
CN-108883072-A Granular preparation of 5-methyl-1-phenyl-2- (1H) -pyridone and preparation method thereof 霍夫曼-拉罗奇有限公司 2018-11-23 CN claimed
EP-1539155-B1 STABLE CREAM PREPARATIONS OF PHENYL-PYRIDONE COMPOUNDS FOR TOPICAL APPLICATION MEPHA AG (CH) 2008-04-02 EP claimed
EP-0866656-B1 USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS MARGOLIN SOLOMON B (US) 2007-04-25 EP claimed
US-20060039931-A1 Stable cream preparations of phenyl-pyridone compounds for topical application MEPHA AG (CH) 2006-02-23 US claimed
EP-1069898-B1 TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS MARGOLIN SOLOMON B (US) 2004-05-12 EP claimed
EP-0813409-B1 TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS MARGOLIN SOLOMON B (US) 2004-05-06 EP claimed
EP-0702551-B1 COMPOSITIONS AND METHODS FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS MARGOLIN SOLOMON B (US) 2002-09-25 EP claimed
US-5962478-A ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE INTERMUNE, INC. 1999-10-05 US claimed
US-20260042765-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORP (US) 2026-02-12 US disclosed
US-20250367178-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF AVALYN PHARMA INC (US) 2025-12-04 US disclosed
US-4052509-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-10-04 US disclosed
US-4042699-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-08-16 US disclosed
US-3974281-A ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS AFFILIATED MEDICAL RESEARCH, INC. (US) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299698-A1 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) CHAT, PNPO, PLPBP ALDH1A1 1343/4885SMN1; SMN2 1338/4885KDM4E 3737/4885
US-20260042765-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS MAP2K2, TTK, MAP2K5 ALDH1A1 2069/4885SMN1; SMN2 4312/4885KDM4E 212/4885
US-20060039931-A1 Stable cream preparations of phenyl-pyridone compounds for topical application PNPO, APOB, PLPBP ALDH1A1 1154/4885SMN1; SMN2 2468/4885KDM4E 1762/4885
US-20250367178-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK ALDH1A1 167/4885SMN1; SMN2 606/4885KDM4E 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.